Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine.
The 1986-87 outbreak of paralytic poliomyelitis in Senegal, with 676 reported cases, provided an opportunity to evaluate the efficacy of an enhanced-potency inactivated poliovirus vaccine (N-IPV) in the Kolda region, where this vaccine has been used since 1980. 89 cases, confirmed to have poliomyelitis with residual paralysis, were enrolled in a case-control study, up to 5 matched controls being obtained for each case. The clinical efficacy for one dose of N-IPV was 36% (95% confidence interval 0%, 67%) and for two doses was 89% (95% CI 62%, 97%).
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D004168:Diphtheria Toxoid / Q000008:administration & dosage / Q000276:immunology / Q000592:standards*; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D004196:Disease Outbreaks / Q000517:prevention & control*; D004338:Drug Combinations / Q000008:administration & dosage / Q000276:immunology / Q000592:standards; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D010567:Pertussis Vaccine / Q000008:administration & dosage / Q000276:immunology / Q000592:standards*; D010865:Pilot Projects; D011051:Poliomyelitis / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage / Q000276:immunology / Q000592:standards*; D012424:Rural Population; D012621:Seasons; D012675:Senegal; D013745:Tetanus Toxoid / Q000008:administration & dosage / Q000276:immunology / Q000592:standards*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology / Q000592:standards; D017778:Vaccines, Combined
C051021:DTPP vaccine; D004168:Diphtheria Toxoid; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D004338:Drug Combinations; D010567:Pertussis Vaccine; D011054:Poliovirus Vaccine, Inactivated; D013745:Tetanus Toxoid; D014613:Vaccines, Attenuated; D017778:Vaccines, Combined